“Schistosomiasis ranks among the most devastating poverty related neglected diseases - and a schistosomiasis vaccine would be a game changer both for global public health and poverty reduction,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. A team of researchers at the George Washington University have received funding from the National Institutes of Health for a Phase Ib clinical trial for a Schistosomiasis vaccine in an endemic area of Brazil. Take a look at this article to read more about the Schistosoma Vaccine.
Schistosoma Vaccine to Enter Phase Ib Clinical Trial
Latest News
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).